B+
Bull case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
SHC
Sotera HealthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-11-04
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+55.7
Score
AI commentary
SHC closed November 3 at the packet's $16.03 anchor, about 9.6% below the prior $17.74 close, despite the modest earnings beat. Historical prices Coverage linked the selloff to European demand concerns and unchanged guidance, but that attribution is interpretive. Market coverage No verified post-print analyst revision is available. The sentiment numeric fields are unavailable-data placeholders, not measured neutral readings. The deterministic prior shifted from neutral to negative, supporting caution rather than extrapolation from the beat.
RankAlpha Sentiment Codex - 2026-11-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystEuropean medical-device demand weaknessMedium impact
On the Q3 call, management said customer softness that began in Q3 persisted into Q4, primarily in Europe, while U.S. demand was relatively stable. Whether that weakness deepens is the immediate downside test. Call transcript
2027-02-28eventDelivery against reaffirmed FY2026 outlookMedium impact
Despite Q3 revenue growth of 4.4% and adjusted EPS of $0.29, Sotera reaffirmed—not raised—FY2026 constant-currency revenue growth of 5.25%–6.75% and adjusted EBITDA growth of 5.75%–7.25%. Delivery against those ranges is the next substantive test; the date is an estimate, not an announced release date. [#8-K-2026-11-03] [#SEC-8K-2026-11-03] Company release
2027-06-30catalystSterilization mix and cash-flow durabilityHigh impact
Q3 constant-currency revenue rose 8.2% at Sterigenics and 9.2% at Nelson Labs, but fell 11.5% at Nordion on expected Co-60 harvest timing. Sustained segment growth, normalization of harvest timing, and conversion of the planned capital-spending step-down into cash flow remain unproven. [#SEC-8K-2026-11-03] Company release
Recommendation
N/A
No formal recommendation provided.
As of 2026-11-04 • Updated nightlySource: Internal modelMethodology